Rigel Pharmaceuticals Inc
A South San Francisco biotechnology company that develops and sells prescription medicines for blood disorders and cancer. Its FDA-approved drugs include Tavalisse for immune thrombocytopenia (a low blood-platelet condition) and Rezlidhia for a form of acute myeloid leukemia. Founded in 1996, the company shares its name with Rigel, a brilliant blue star in the Orion constellation whose Arabic name means "the foot of the giant."
Bought 32.7K · Sold 484.6K
Bought 650.0K · Sold 7.7K
Granted 1.17M · Bought 1.11M · Sold 82.6K
Bought 200.0K
Granted 50.0K
Granted 176.7K · Sold 176.7K
Granted 100.0K
Granted 372.2K · Bought 50.0K · Sold 21.8K
Granted 75.0K
Granted 50.0K · Sold 5.4K
Granted 378.1K · Sold 23.8K
Granted 50.0K · Sold 5.2K
Granted 45.0K · Sold 107.0K
Granted 248.2K · Sold 2.8K
Granted 25.0K · Bought 10.0K
Granted 38.6K
Granted 25.0K
Granted 114.5K · Sold 4.0K
Granted 108.3K
Granted 108.3K
Granted 89.5K
Granted 77.0K · Sold 5.0K
Granted 7.0K
Granted 5.8K
Bought 2.0K
Sold 10.0K
Granted 169.5K · Sold 189.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Biotechnology Value Fund II LP +5 co-filersSee Explanation of Responses, 10% owner · 4 transactions | — | 6.96Mas of Nov 2013 | — | 32.7K | 484.6K |
| Deerfield Capital LP +6 co-filersReporting owner · 8 transactions | — | 6.74Mas of Jun 2011 | — | 650.0K | 7.7K |
| Rodriguez Raul RCEO, President, Director · 23 transactions | — | 279.6K | 1.17M | 1.11M | 82.6K |
| Mayer Eldon C. IIIEVP & Chief Commercial Officer · 3 transactions | — | 215.0Kas of Sep 2018 | — | 200.0K | — |
| Gower James MCEO & Board Chairman, Director · 2 transactions | — | 180.7Kas of Jan 2009 | 50.0K | — | — |
| Maynard Ryan DEVP & CFO · 13 transactions | — | 100.0Kas of Nov 2017 | 176.7K | — | 176.7K |
| Kotzin Brian L.Director · 4 transactions | — | 100.0Kas of May 2024 | 100.0K | — | — |
| Schorno Dean LEVP & Chief Financial Officer · 20 transactions | — | 78.8K | 372.2K | 50.0K | 21.8K |
| Lyons Gary ADirector · 3 transactions | — | 75.0Kas of May 2023 | 75.0K | — | — |
| Dummer WolfgangEVP & CMO · 2 transactions | — | 72.5Kas of Feb 2023 | 50.0K | — | 5.4K |
| Santos David AEVP, Chief Commercial Officer · 13 transactions | — | 62.0K | 378.1K | — | 23.8K |
| Vance DollyEVP Corp. Affairs, G.C., Sect. · 3 transactions | — | 60.3Kas of Jan 2022 | 50.0K | — | 5.2K |
| Payan Donald GEVP, Pres. Discovery&Research, Director · 11 transactions | — | 53.0Kas of Aug 2016 | 45.0K | — | 107.0K |
| Furey Raymond J.EVP, GC, CCO & Corp Sec · 8 transactions | — | 50.9K | 248.2K | — | 2.8K |
| Goodwin Bradford SDirector · 8 transactions | — | 35.0Kas of May 2021 | 25.0K | 10.0K | — |
| Rojkjaer LisaEVP, Chief Medical Officer · 4 transactions | — | 34.0K | 38.6K | — | — |
| Katkin KeithDirector · 1 transaction | — | 25.0Kas of May 2021 | 25.0K | — | — |
| Moos Walter HDirector · 9 transactions | — | 18.5K | 114.5K | — | 4.0K |
| Lapointe Anthony GreggDirector · 6 transactions | — | 18.3K | 108.3K | — | — |
| Wasman JaneDirector · 6 transactions | — | 18.3K | 108.3K | — | — |
| Hannah Alison L.Director · 6 transactions | — | 16.4K | 89.5K | — | — |
| Ali-Jackson KamilDirector · 7 transactions | — | 10.1K | 77.0K | — | 5.0K |
| Frohlich Mark WDirector · 2 transactions | — | 7.0K | 7.0K | — | — |
| Miller Michael PatrickDirector · 1 transaction | — | 5.9K | 5.8K | — | — |
| Grossbard Elliott BSr. VP Medical Development · 1 transaction | — | 2.0Kas of May 2007 | — | 2.0K | — |
| Cabatuan NelsonPrincipal Accounting Officer · 1 transaction | — | 58as of Oct 2018 | — | — | 10.0K |
| Duliege Anne-MarieEVP & Chief Medical Officer · 10 transactions | — | 0as of Sep 2018 | 169.5K | — | 189.5K |
| Frazier Alan DDirector · 1 transaction | — | 0as of Nov 2005 | — | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +932.7K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.